Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Aug 4, 2025 | Artemis Global Select Fund (converted to Artemis SmartGARP Global Smaller Companies Fund on October 6, 2025) | 4.2% | -7.5% | SDZ SW, TXN | currencies, Cycles, Global Equities, selectivity, tariffs | The commentary highlights the influence of economic and political cycles on global asset prices, particularly tariffs, fiscal policy, and currency movements. Management stresses selective stock picking across regions and sectors as macro conditions evolve. Cyclical recovery potential is balanced against valuation discipline. | View | |
| 2024 Q4 | Dec 31, 2024 | Hardman Johnston International Equity | -3.3% | 13.4% | 8750 JP, AZN LN, MC FP, MELI, NEX FP, NOD NO, NVO, SDZ SW, STAN LN, TEAM, TSM, UCB BB | - | View | ||
| 2025 Q3 | Oct 21, 2025 | Hardman Johnston International Equity | 8.5% | 36.2% | 6501 JP, 7269 JP, DTE GR, HDFCB IN, ICICIBC IN, IFX GR, MELI, NVO, PRX NA, PRY IM, SDZ SW, STM, TEAM, TSM, UCB BB | AI, Europe, healthcare, International Equities, semiconductors | The fund benefited from strong stock selection in Europe and Asia, led by AI-related semiconductor names like TSMC and STMicroelectronics. Healthcare and consumer discretionary sectors also contributed, while financials and Japan detracted. The outlook highlights opportunity in undervalued international equities amid tariff normalization and AI-led productivity investment. | SUZUKI PROS SDZ UCB |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | Fund Letters | Cassandra A. Hardman | Sandoz Group Ltd. | Health Care | Pharmaceuticals | Bull | Swiss Exchange | Biosimilars, Generics, Glp1, pipeline, Regulation | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||